RxDoctor Payments Data

Babajide Runsewe, MD

Family Medicine · Windsor Mill, MDNPI 1124220561

Payments from drug & device makers

$1,042in general payments, 2019–2025

Across 49 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$249
  • Nestle Healthcare Nutrition Inc.$190
  • Otsuka America Pharmaceutical, Inc.$181
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136
  • Pfizer$85
  • Biohaven Pharmaceuticals, Inc.$44
  • plus $156 from 6 others

What the payments were for

  • Food & beverage$1,042100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,042 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$52,601
Medicare patients
91
Services billed
631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$37,766
XareltoRivaroxaban13$9,221
Atorvastatin Calcium116$1,797
Potassium Chloride22$1,274
Rosuvastatin Calcium36$1,004
Metoprolol Succinate50$722
Amlodipine Besylate100$695
Gabapentin24$650
Famotidine30$511
Levothyroxine Sodium39$456
Fluticasone Propionate19$424
Losartan Potassium57$420
Metformin Hcl66$412
Lactulose21$380
Mirtazapine17$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$37,76633 claims
Johnson & JohnsonXarelto$41$9,22113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Windsor Mill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →